FIELD: medicine.
SUBSTANCE: present invention concerns medicine, namely - to oncology and can be used for treatment of a cancer at a mammal. The way under the invention includes introduction of ditosylate salt N-{3-chloride-4-[(3-fluobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethylene]amino}methyl)-2-furyl]-4-quinazoline amine (chemical combination 1) monohydrate and capecitabine.
EFFECT: depression of risk of advance of disease.
2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| COMBINATIONS OF ANTI-CANCER MEDICINES | 2015 |
|
RU2733401C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| COMBINATION TREATMENT | 2014 |
|
RU2666999C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
